Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

Launched by UNIVERSITY OF ALBERTA · Jun 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a third dose of the MMRV vaccine (which protects against measles, mumps, rubella, and varicella) can help improve immunity in women who may not have enough protection after receiving the standard two doses. Researchers are concerned that some vaccinated individuals, especially in highly vaccinated communities, might still be at risk of getting these infections because their antibody levels are lower than what is considered safe. The study will focus on pregnant women who have had routine testing for rubella antibodies and will look at their immune responses without administering the vaccine directly in the trial.

To be eligible for this study, women must be pregnant and older than 18 years. Participants will be part of a group that includes women who have received a third dose of the vaccine through their regular healthcare, allowing researchers to learn more about how this additional dose may help improve immune responses. This study is currently recruiting participants, and it is important for eligible women to consider joining to contribute to our understanding of vaccine effectiveness in protecting against these diseases.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women who are pregnant and have undergone routine prenatal screening for rubella antibodies.
• Exclusion Criteria:
• • Women younger than 18 years of age